Indications de la chimiothérapie dans le traitement des cancers urologiques métastatiques

25 novembre 2008

Auteurs : C. Théodore
Référence : Prog Urol, 2008, 18, S219, suppl. S7


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser






Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 2004 ;  171 : 1071-1076 [cross-ref]
Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 2005 ;  23 : 832-841 [cross-ref]
Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 ;  92 : 205-216 [cross-ref]
Gignac G.A., Morris M.J., Heller G., Schwartz L.H., Scher H.I., et al. Assessing outcomes in prostate cancer clinical trials: a twentyfirst century tower of Babel Cancer 2008 ;  113 : 966-974 [cross-ref]
Mazumdar M., Bajorin D.F., Bacik J., Higgins G., Motzer R.J., Bosl G.J. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy J Clin Oncol 2001 ;  19 (9) : 2534-2541 [cross-ref]
3 CTC version 3: ctc_v30.html.
Motzer R.J., Bolger G.B., Boston B., et al. Testicular cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw 2006 ;  4 : 1038-1058
Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 ;  351 : 1502-1512 [cross-ref]
Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 1996 ;  14 : 1756-1764 [cross-ref]
Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 2006 ;  42 : 50-54 [cross-ref]
von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 2005 ;  23 (21) : 4602-4608 [cross-ref]
Sternberg C.N., Calabrò F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 2001 ;  92 : 2993-2998 [cross-ref]


© 2008  Elsevier Masson SAS. Tous droits réservés.